R&D PIPELINE

Catalyse Development

Concept
- TB host & pathogen marker screening
- LAM RDTs for broad use cases
- Host biomarker and phenotypic ID tool landscaping
- Non-HRP2 marker landscaping
- Open-access biomarker database (Bm2Dx)
- MAPDx platform (MSF)
- Typhoid & other pathogen Dx landscaping
- Simplified blood culture landscaping
- Self-testing (TBD)
- Gonorrhea Dx (drug stewardship)
- UTI landscaping & project definition
- Substandard & falsified medicine screening
- WHO R&D Blueprint pathogen landscaping
- Yellow fever & meningitis Dx for vaccine admin landscaping
- WHO outbreak landscaping & disease commodity packages

Feasibility
- LAM sputum monitoring (Otsuka)
- Triage POC test (TBD)
- Centralized use: Next Generation Sequencing
- POC molecular ID & DST (Blink Dx)
- RDT for recent P. vivax infections (WEHI, Mologic)
- Schistosoma: RDT (Mologic)
- Buruli: Mycolactone RDT (DDTD)
- RNA polyvalent POC (Blink Dx)
- cAg RDT format (multiple partners)
- Xpert Carba-R v2 (Cepheid)
- AMR connectivity toolkit
- Semi-open molecular platform for Lassa (Altona, Cepheid)
- POC multi-analyte, polyvalent (Blink DX)
- Yellow fever rapid test (Mologic/IPD)

Development
- LAM RDTs for HIV+ (Fujifilm)
- Decentralized use: Xpert XDR (Cepheid)
- Centralized use: Flurotype XDR (Hain)
- GeneXpert Omni (Cepheid)
- eHealth clinical decision support toolbox
- Multiplexed immunoassay (Chembio)
- Improved RDTs for P. falciparum and P. falciparum plus P. vivax (SD/ABBott)
- Buruli: LAMP (DDTD, NMIMR)
- Buruli: Ag capture (SD, Swiss TPH)
- HAT: malaria combo RDT (SD)
- RNA TrueNAT (Molbio)

Evaluation
- TrueNAT (Molbio)
- Centralized DST (Roche, Abbott, BD, Hain)
- Centralized use: Flurotype XDR (Hain)
- eHealth clinical decision support toolbox
- Multiplexed immunoassay (Chembio)
- Improved RDTs for P. falciparum and P. falciparum plus P. vivax (SD/ABBott)
- Buruli: LAMP (DDTD, NMIMR)
- Buruli: Ag capture (SD, Swiss TPH)
- HAT: malaria combo RDT (SD)
- RNA TrueNAT (Molbio)

Demonstration
- hsRDT in maternal & child health (multiple partners)
- CRP use in Viet Nam
- HAT: Second generation RDT (SD)
- RNA capillary blood (Cepheid)
- Leishmaniasis: Rk28 RDT for WHO (CTK Biotech)
- RNA (genedrive)
- Serology RDTs for WHO PQ (multiple partners)
- RNA DBS for WHO (multiple partners)
- cAg test of cure (Abbott)
- Lassa RealStar 2.0 ERPD for WHO (Altona)

Disease programmes
- Tuberculosis
- Malaria & Fever
- Antimicrobial Resistance
- Hepatitis C & HIV
- Pandemic Preparedness
- Neglected Tropical Diseases

Last updated: March 2019